The Global "H1N1 (swine flu) Vaccination Market" is estimated to reach at a high CAGR during the forecast period (2022-2029).
Swine flu is an infection of the respiratory system caused by influenza viruses. These viruses also infect the respiratory system of pigs causing barking cough, decrease in appetite, nasal secretions, and listless behaviour. Influenza viruses can also be transmitted to humans. Swine flu viruses can induce genetic changes or mutations so that these are easily transmissible among humans. In April 2009, a swine flu outbreak was first detected in Mexico and was caused due to the H1N1 virus.
The global H1N1 (swine flu) vaccination market growth is driven by the increasing preservance of epidemic H1N1 infection and declining immunity among the geriatric population and technological advancements in the vaccines are the key driving factors in the market.
Rising awareness among people will stoke market growth in the forecast period
The market is growing tremendously due to increased awareness of vaccination from diseases. For instance, according to centres for disease control and prevention, in 2009 during the pandemic approximately 60.8 million cases, 274,304 hospitalizations and 12,469 deaths occurred due to H1N1 swine flu. There have been tremendous technological advancements in the field of vaccination in the last decade. For instance, in 2006, the U.S. Department of Health and Human Services awarded $1 billion in funding to a number of vaccine makers, including GlaxoSmithKline, Novartis, and MedImmune, to develop alternative production methods.
Increasing incidences of epidemic H1N1 infection and declining immunity among the geriatric population drive the market growth
The H1N1 virus is contagious and can spread widely through small droplets of saliva from coughs or sneezes of the infected person. H1N1 virus causes damage to the respiratory system including the nose, lungs, and throat. The H1N1 virus is a Ribonucleic acid (RNA) virus belonging to the Orthomyxoviridae family. In the year 2009, a strain of swine flu called "H1N1" infected many people around the world.
According to the World Health Organization (WHO), annually about 3 to 5 million cases of severe illness and about 2,90,000 to 6,50,000 respiratory deaths are due to seasonal influenza. In the case of industrialized countries, most of the deaths due to influenza occur among people above 65 years of age. Seasonal influenza illnesses range from mild to severe and even death. Thus these factors are driving the market growth in the forecast period.
Shortage of new antibiotics is likely to hinder the market growth in the forecast period
However, about one in three people who are taking the vaccine get a sore arm from the shot, some with a little redness or even swelling. Some 10% to 15% of people feel tired or get a headache, some may even run a low fever. This factor is expected to hamper the growth of the market in the forecast period.
A CDC report on the 2009 swine flu outbreak estimates there were 60.8 million H1N1 cases nationwide in the first year of the outbreak. COVID-19 has infected around 4 million people in the U.S. Thus the pandemic does not affect the market in the forecast period. But an analysis from JAMA Internal Medicine of CDC data said the number of people infected is likely two to 24 times as high as the confirmed case count. That would put our 4 million cases anywhere from 8 million to 96 million cases, which would considerably change the context of the claim. And while the H1N1 cases appear to outnumber COVID-19 cases, at least for now, the swine flu doesn't come anywhere close to being as deadly. Thus, the pandemic does not affect the market in the forecast period.
The influenza segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
Influenza is highly a contagious and communicable disease, transmission of the disease can easily occur at public places by infected patients who serve as carriers of the disease. The disease burden varies from region to region with temperate climate regions facing season influenza breakouts. The management and treatment of the disease are challenging in tropical regions where influenza occurs throughout the year thus causing constant breakouts.
High-risk individuals for influenza consist of pregnant women, children, the elderly population, immunosuppressed patients that suffer from chronic medical conditions, and healthcare workers. The treatment of influenza consists of various antiviral drugs that aid in the reduction of complications and fatalities such as death.
According to data from the Centers for Disease Control and Prevention, about 85 laboratories confirmed pediatric deaths were seen in the District of Columbia, Puerto Rico, and 33 other states. The mortality for the U.S. due to influenza was 4,605 in the year 2016 indicating 1.4 deaths per 100,000 individuals. Despite influenza being easily treatable, there are cases where adequate care and diagnosis plays a vital role in the treatment of the disease. Timely diagnosis and appropriate treatment are key in eradicating the epidemic disease globally.
Vaccination is a major way of immunizing individuals against infectious disease to avoid serious complications, especially in immunosuppressed patients who serve as high-risk individuals. Mutation of the virus serotype proves to be a major hindrance as vaccination in such cases becomes difficult putting the individual at risk of contracting the virus. Thus, with changes in virus type, it is crucial to detect its presence in patients and administer timely medication to prevent fatalities. Thus, the demand for influenza diagnostics products has been rising accelerating the market growth for the same.
Meningococcal has positive market growth in the forecast period. The increasing prevalence of meningitis is one of the major factors expected to drive the market. According to the Centers for Disease Control and Prevention (CDC), around 1.2 million cases of bacterial meningitis are projected to occur globally every year. Increasing initiatives by government and regulatory authorities to combat the rising prevalence of meningitis is expected to boost market growth. For instance, in May 2018, “Defeating meningitis by 2030” was introduced at the World Health Assembly by Eastern Mediterranean and African regions to develop a strategic roadmap for meningitis prevention by prioritizing areas for research and enhanced control activities. These factors are driving the growth of the market in the forecast period.
North America region holds the largest market share global H1N1 (swine flu) vaccination market
North America region is dominating the global H1N1 (swine flu) vaccination market accounted for the largest market share in 2020, the developed research infrastructure in these regions. The U.S. holds the largest market for H1N1 vaccination, followed by Canada, in North America. For instance, in December 2019, NACI (National Advisory Committee on Immunization) published scientific information and recommendation on MenB-fHBP (bivalent factor-H binding protein meningococcal serogroup B) vaccine (Trumenba). The presence of a strong pipeline of meningococcal vaccines is expected to maintain a significant market share in the region.
For instance, according to the Centers for Disease Control (CDC), about 8 per cent of the United States population gets sick from the flu. In addition, approximately 31.4 million people visit the doctor and 200,000 people end up in the hospital every flu season.
The H1N1 (swine flu) Vaccination market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include AstraZeneca plc, Medimmune, GlaxoSmithKline, Novartis, and Sanofi Pasteur. Baxter, Sinovac, Commonwealth Serum Laboratories, Zydus Cadila among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the H1N1 (swine flu) vaccination market globally.
H1N1 (swine flu) Vaccination Market Key Companies to Watch
Overview: Sanofi Pasteur SA develops, manufactures, and supplies vaccines in France and internationally. The company provides vaccines for bacterial and viral diseases, including pertussis, diphtheria, typhoid fever, poliomyelitis, influenza, and mumps. It has production sites in France, the United States, Canada, China, Thailand, and Argentina. The company was formerly known as Aventis Pasteur S.A. and changed its name to Sanofi Pasteur SA in 2004. The company was founded in 1990 and is headquartered in Lyon, France. The company is headquartered in Lyon, France. Sanofi Pasteur SA operates as a subsidiary of Sanofi-Aventis.
Product Portfolio: The Company’s portfolio is comprised of the largest flu vaccine maker in the world and it's working on improving flu vaccines to prepare for a potential influenza pandemic.
Key Development: In July 2018, Sanofi Pasteur, the vaccine division of Sanofi, launch its 4-strain influenza vaccine FluQuadri in India. FluQuadri will be India’s first quadrivalent vaccine to provide broader protection against influenza to populations above 3 years of age.
Get your free sample proposal with a single click!